Dr. Miller is the Chief Scientific Officer and is responsible for all facets of Artizan’s research and development organization and portfolio. Prior to joining Artizan in 2019, he was Chief Scientific Officer at Synlogic where he established the company’s research team and helped guide it to advance a novel, engineered, live microbial biotherapeutic platform from idea to first-in-human studies in under three years. Previously, Dr. Miller was the Vice President of Infection Biology at AstraZeneca where he was responsible for the early discovery portfolio and strategy, while also leading several external collaborations. Prior to AstraZeneca, Dr. Miller was the Chief Scientific Officer for Antibacterial Research at Pfizer, leading discovery teams that produced eight drug development candidates, provided critical research support for several successful marketed antibiotics including Zithromax and Zyvox and advanced a novel oxazolidinone (sutezolid) for tuberculosis into Phase 2 studies. A microbial geneticist by training, he began his professional career at the Warner-Lambert Company in Ann Arbor, Michigan, where he integrated cutting edge molecular-genetic approaches into a traditional antibacterial drug discovery program and established novel target discovery projects. His work there led to new insights into the mechanisms by which bacteria sense and respond to antibiotics and other environmental agents. Dr. Miller has served as a member of the Institute of Medicine’s Forum on Microbial Threats and also is a scientific advisor to the CARB-X antibacterial funding initiative as well as the Bill and Melinda Gates Foundation in the area of tuberculosis drug discovery. He received his Ph.D. in Microbiology and Immunology from the Albany Medical College and conducted post-doctoral studies in yeast genetics at the National Institutes of Health.
Prior to Artizan’s inception, Mr. Rosen spent 12 years in venture capital, most recently leading the program-related venture capital investment function for the Bill & Melinda Gates Foundation in Seattle. Mr. Rosen spent a decade with Intersouth Partners, where he worked his way from intern to Partner on the life sciences investment team. Prior to joining Intersouth, he spent 15 years in clinical, research and financial positions in the health care and biotechnology sectors. His research experience includes programs at the Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill (UNC), the National Cancer Institute, Duke University Medical Center and its Comprehensive Cancer Center. Mr. Rosen also managed clinical trials at a privately held contract research organization, which led to FDA-approved products. He spent several years as an equity research analyst at Brean Murray & Co., covering biopharmaceuticals, genomics, generics, drug delivery and medical device companies. Prior to his research and Wall Street functions, Mr. Rosen spent five years in Emergency Medical Services as a mountain search & rescue and ambulance medic. He currently serves on numerous boards and advisory committees, including the UNC’s Public Health Foundation Board (Emeritus, Chairman) and Dean’s Advisory Council for the Gillings School of Global Public Health at UNC, the Carolina Research Ventures Advisory Board and the Oversight Committee for the Duke-Coulter Translational Partners Program. Mr. Rosen holds a B.A. from Duke University and an M.B.A. from UNC’s Kenan-Flagler School of Business where he was a Carolina Venture Fellow and recipient of the Frank Hawkins Kenan Award for Excellence. He received his M.S.P.H. from the UNC School of Public Health, where his thesis focused on the relationship between technology transfer in biotechnology and venture capital investment. In 2010, he was awarded the Eisenhower Fellowship for which he designed and executed a program to evaluate the prospects for health care innovation in China and Southeast Asia.